Vogel Isabel, Verbinnen Bert, Van Gool Stefaan, Ceuppens Jan L
Laboratory of Clinical Immunology, KULeuven, University Hospital Gasthuisberg, 3000 Leuven, Belgium; and.
Laboratory of Clinical Immunology, KULeuven, University Hospital Gasthuisberg, 3000 Leuven, Belgium; and Childhood Immunology, KULeuven, University Hospital Gasthuisberg, 3000 Leuven, Belgium.
J Immunol. 2016 Jul 15;197(2):533-40. doi: 10.4049/jimmunol.1502039. Epub 2016 Jun 10.
Blocking of costimulatory CD28/B7 and CD40/CD40L interactions is an experimental approach to immune suppression and tolerance induction. We previously reported that administration of a combination of CTLA-4Ig and MR1 (anti-CD40L mAb) for blockade of these interactions induces tolerance in a fully mismatched allogeneic splenocyte transfer model in mice. We now used this model to study whether regulatory T cells (Tregs) contribute to immune suppression and why both pathways have to be blocked simultaneously. Mice were injected with allogeneic splenocytes, CD4(+) T cells, or CD8(+) T cells and treated with MR1 mAb and different doses of CTLA-4Ig. The graft-versus-host reaction of CD4(+) T cells, but not of CD8(+) T cells, was inhibited by MR1. CTLA-4Ig was needed to cover CD8(+) T cells but had only a weak effect on CD4(+) T cells. Consequently, only the combination provided full protection when splenocytes were transferred. Importantly, MR1 and low-dose CTLA-4Ig treatment resulted in a relative increase in Tregs, and immune suppressive efficacy was abolished in the absence of Tregs. High-dose CTLA-4Ig treatment, in contrast, prevented Treg expansion and activity, and in combination with MR1 completely inhibited CD4(+) and CD8(+) T cell activation in a Treg-independent manner. In conclusion, MR1 and CTLA-4Ig act synergistically as they target different T cell populations. The contribution of Tregs to immune suppression by costimulation blockade depends on the concentration of CTLA-4Ig and thus on the degree of available CD28 costimulation.
阻断共刺激分子CD28/B7和CD40/CD40L的相互作用是一种诱导免疫抑制和耐受的实验方法。我们之前报道过,联合使用CTLA-4Ig和MR1(抗CD40L单克隆抗体)阻断这些相互作用可在小鼠完全不匹配的同种异体脾细胞移植模型中诱导耐受。我们现在利用该模型研究调节性T细胞(Tregs)是否有助于免疫抑制,以及为何两条通路必须同时阻断。给小鼠注射同种异体脾细胞、CD4(+) T细胞或CD8(+) T细胞,并用MR1单克隆抗体和不同剂量的CTLA-4Ig进行治疗。MR1可抑制CD4(+) T细胞而非CD8(+) T细胞的移植物抗宿主反应。需要CTLA-4Ig来覆盖CD8(+) T细胞,但对CD4(+) T细胞的作用较弱。因此,当移植脾细胞时,只有联合使用才能提供完全保护。重要的是,MR1和低剂量CTLA-4Ig治疗导致Tregs相对增加,且在没有Tregs的情况下免疫抑制效果消失。相比之下,高剂量CTLA-4Ig治疗可阻止Treg扩增和活性,与MR1联合使用可独立于Tregs完全抑制CD4(+)和CD8(+) T细胞活化。总之,MR1和CTLA-4Ig协同作用,因为它们作用于不同的T细胞群体。Tregs对共刺激阻断诱导免疫抑制的作用取决于CTLA-4Ig的浓度,从而取决于可用CD共刺激的程度。 28